ClinicalTrials.Veeva

Menu
V

Valkyrie Clinical Trials | Los Angeles, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tislelizumab
Pembrolizumab
Zanubrutinib
Ezabenlimab
Zongertinib
BNT327
Cetuximab
Trilaciclib
INCB099280
mFOLFIRINOX

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

45 of 54 total trials

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Drug: BGB-16673

Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously a...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: Carfilzomib
Drug: Dexamethasone

This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard d...

Enrolling
Breast Cancer
TNBC - Triple-Negative Breast Cancer
Drug: Capecitabine
Drug: PCS6422 and capecitabine

The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how...

Enrolling
Advanced Solid Tumors
Drug: WGI-0301

This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has...

Enrolling
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Drug: BI 765049
Drug: ezabenlimab

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Drug: 5-Fluorouracil
Drug: Tislelizumab

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel
Locations recently updated

This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other place...

Enrolling
Ovarian Neoplasms
Carcinoma, Non-Small-Cell Lung
Drug: disitamab vedotin

The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify...

Active, not recruiting
Advanced Solid Tumors
Drug: adagrasib
Drug: INCB099280

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-...

Active, not recruiting
Non-small Cell Lung Cancer
NSCLC
Drug: Placebo
Drug: Tislelizumab

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without...

Enrolling
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: pemetrexed
Drug: LBL-007

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid...

Enrolling
Advanced Solid Tumor
Drug: Valemetostat tosylate
Drug: T-DXd

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in...

Enrolling
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Endometrial Cancer
Biological: vudalimab

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Lenalidomide

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Enrolling
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Drug: ABP 234
Drug: Pembrolizumab (EU)

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Active, not recruiting
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head...

Enrolling
Recurrent or Metastatic Solid Tumors
Drug: Ifinatamab deruxtecan

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advance...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
High-grade Serous Ovarian Carcinoma (HGSOC)
Drug: BMS-986463
Locations recently updated

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for who...

Enrolling
Neoplasm Metastasis
Non-Small Cell Lung Cancer
Drug: zongertinib

This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment...

Enrolling
Solid Tumors
Drug: BI 1703880
Drug: Ezabenlimab

Trial sponsors

BeiGene logo
Boehringer Ingelheim logo
Incyte logo
BioNTech logo
Bristol-Myers Squibb (BMS) logo
Daiichi Sankyo logo
G
Summit Therapeutics logo
I
Akeso logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems